

B66

island-shaped discontinuous film formed under coating, surface of film  
oxidised to form peroxide residual groups, vinyl type hydrophilic monomer

Patent Assignee: SUMITOMO BAKELITE CO (SUMB )

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 4215760	A	19920806	JP 90419191	A	19901213	199238 B

Priority Applications (No Type Date): JP 90419191 A 19901213

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
JP 4215760	A	5	A61L-033/00	

Abstract (Basic): JP 4215760 A

An island-shaped discontinuous film is formed as an under coating. The surface of the film is oxidised to form peroxide residual gps. A vinyl type hydrophilic monomer(s) is then graft-copolymerised with the surface. The monomer is pref. added with at least one of di- and higher-functional vinyl monomers and graft-copolymerised.

Alternatively, an island-shaped discontinuous film having free prim. and/or sec. amino gps. on the surface is formed as an under coating. Ethylene oxide, instead of vinyl monomer, is graft-copolymerised solely or with other copolymerising olefin oxides.

Residual gps. for the under coating include -NH<sub>2</sub>, -NRH (where R = -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -C<sub>3</sub>H<sub>7</sub> or other alkyl or phenyl), -CH<sub>2</sub>(-) and -CRH(-) (R = -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -C<sub>3</sub>H<sub>7</sub> or other alkyl or phenyl). Polymers for the under coating include polyethylene, polypentene, acryl resin, polyacrylonitrile, polystyrene, AS resin, PBT resin and ethylene-propylene terpolymer. Polymers for the graft copolymerisation of olefin oxide monomers include polylysine, polypropylene imine and albumin polymers made insoluble by crosslinking with aldehydes, isocyanates and carboxylic acids.

USE/ADVANTAGE - Gives improved surface lubricity and high compatibility with tissues of the body. The appliances and implant materials obtd. have high functionality, strength and safety.

Dwg. 0/0

? S PN=JP 4244015

S4 1 PN=JP 4244015

? T 4/3,AB/1

4/3,AB/1

DIALOG(R) File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

009210299

WPI Acc No: 1992-337721/\*199241\*

XRAM Acc No: C92-150272

XRPX Acc No: N92-257670

Hybrid-type artificial pancreas prepn. - by including and fixing pancreatic Langerhans islet with polymer and cultivating in-vitro to avoid hyperglycaemia of animals, which have under-gone organ transplantation, etc.

Patent Assignee: SEKISUI CHEM IND CO LTD (SEKI )

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
-----------	------	------	-------------	------	------	------

JP 4244015 A 19920901 JP 9132877 A 19910227 199241 B  
 JP 3204675 B2 20010904 JP 9132877 A 19910227 200152

Priority Applications (No Type Date): JP 90405007 A 19901221

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 4244015	A		6	A61K-009/00	
JP 3204675	B2		6	A61L-027/00	Previous Publ. patent JP 4244015

Abstract (Basic): JP 4244015 A

Prepn. comprises inclusion and fixation of pancreatic Langerhans islet with natural and/or synthetic polymer and subsequent cultivation in-vitro for 5 days or more.

Fixing materials from natural polymers employable are agarose, agarose acid hydrolysate, koppa-carrageenan, collagen, gelatin, gellan gum, gum arabic, alginic acid salts, pectin, agar, mannan, fibrin, chitosan, etc.. The materials from synthetic polymers are photo-bridged PVA, isopropyl-acrylamide copolymer polyacrylamide, etc.. Mixed materials are e.g. polyionic complexes such as alginic acid-polylysine and CMC-polylysine. Pref. inclusion is carried out by gelation.

USE/ADVANTAGE - The prepn. solves problems caused by damaged pancreatic Langerhans islet. It can also avoid hypoglycemia of animals which have undergone organ transplant and further prevent the immunoinduction of recipients.

In an example, agarose (0.15g) were added to 3ml Eagle's MEM soln. to make 5 wt. % polymer concn.. This was autoclaved at 121 deg. C for 20 mins. and than the resultant soln. was kept at 40 deg. C. A dispersion liq. of 1000 pancreatic Langerhans islets (isolated from hamster's pancreas by collagenase method) in 0.1 ml Eagles's MEM soln. was added to the soln.. To this was added ca. 20 ml liq. paraffin at 40 deg. C to give a dispersion liq. which was ice cooled into a gel. After addn. of ca. 30 ml Hanks' soln., the mixt. was centrifuged at 2000 rpm for 10 mins. to collect pptd. microcapsules of ca. 50-80 um particle size. Each capsule contained 1-several islets included and fixed. These microcapsules were cultivated in eagle's MEM-5% fetal bovine serum under 5% CO2 at 37 deg. C for 30 days to form hydrid-type artificial pancrea

Dwg.0/0

? S PN=JP 7216000

S5 1 PN=JP 7216000

? T 5/3,AB/1

5/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

010416170

WPI Acc No: 1995-317484/\*199541\*

XRAM Acc No: C95-140942

**Combined prod. of a monoclonal antibody against epithelium growth factor receptor and spacer - selectively recognises only cells producing EGF receptor**

Patent Assignee: KIYOMIZU N (KIYO-I); SHIBAYAGI KK (SHIB-N)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 7216000	A	19950815	JP 9440326	A	19940131	199541 B